Check out the companies making headlines in premarket trading. Bristol-Myers Squibb — The biopharmaceutical stock jumped 5.3% after the Food and Drug Administration approved Cobenfy as a treatment of schizophrenia for adults. It marks the first new type of treatment for the mental disorder in several decades. Novo Nordisk – U.S.-listed shares of the Danish health care company slid 2.9% after JPMorgan said to expect a lower sales figure than Wall Street expects for the third quarter.
This comes after Hindenburg Research revealed it had taken a short position in the company last month, listing "fresh evidence of accounting manipulation" as a reason. Cassava Sciences — Shares tumbled 11.5% after the biotech company settled a case with the Securities and Exchange Commission over "misleading claims" regarding an Alzheimer's clinical trial. Cassava Sciences agreed to pay civil penalties of $40 million dollars.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: AP - 🏆 728. / 51 続きを読む »
ソース: ksatnews - 🏆 442. / 53 続きを読む »
ソース: wjxt4 - 🏆 246. / 63 続きを読む »